West Virginia becomes the first state to lower patient costs by sharing the savings
By Scott LaGanga | April 20, 2021
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to...
Read More
What they are saying: Experts highlight the importance of IP in recent NIST proposal comments
By Megan Van Etten | April 20, 2021
Strong, reliable, and clearly defined intellectual property (IP) protections are the foundation of America’s robust innovation ecosystem that patients across the globe rely on for the research and...
Read More
PhRMA member companies share how they are improving clinical trial diversity
By Dr. Freda Lewis-Hall | April 14, 2021
As part of the biopharmaceutical industry’s efforts to improve health outcomes for patients in underserved communities, PhRMA member companies are identifying ways to improve clinical trial...
Read More
Our three-part approach to build a better health care system
By Stephen J. Ubl | April 13, 2021
On April 3, more than four million Americans received a COVID-19 vaccine — the largest single-day vaccination event in human history. For innovators across the pharmaceutical industry, these...
Read More
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
By Andrew Powaleny | April 12, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...
Read More
Diversifying clinical trials and fighting disease requires equity and trust
By Rebecca Marklund | April 12, 2021
The COVID-19 pandemic has left no person unaffected, but Black Americans have been disproportionately impacted. Black adults are nearly four times more likely to be hospitalized from the virus and...
Read More
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
By Megan Van Etten | April 9, 2021
Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed...
Read More
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
By Stephen J. Ubl | March 31, 2021
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections....
Read More
Data shows that keeping a strong biopharmaceutical industry is important to Americans
By Mark Keida | March 30, 2021
The United States biopharmaceutical industry continues to innovate and discover critical solutions for our toughest health challenges such as the COVID-19 pandemic. America’s global leadership has...
Read More
New report demonstrates the growing importance of partnerships in advancing biomedical innovation
By Abigail Lore | March 24, 2021
As we mark a full year since COVID-19 was declared a global pandemic, it’s impossible to overstate the significance of collaborations. The unprecedented level of strategic collaborative efforts...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
